Vitamin D Tied to Better Assisted Reproductive Therapy Outcomes

Share this content:
Vitamin D Tied to Better Assisted Reproductive Therapy Outcomes
Vitamin D Tied to Better Assisted Reproductive Therapy Outcomes

THURSDAY, Nov. 16, 2017 (HealthDay News) -- For women undergoing assisted reproductive treatment (ART), those who are replete in vitamin D have better outcomes, including live birth, a positive pregnancy test, and clinical pregnancy, according to a review published online Nov. 14 in Human Reproduction.

Justin Chu, M.B.Ch.B., from the University of Birmingham in the United Kingdom, and colleagues conducted a systematic review and meta-analysis of 11 published cohort studies that included 2,700 women and examined the correlation between vitamin D and ART outcomes.

Based on data from seven studies that reported live birth (including 2,026 patients), the researchers found that live birth was more likely in women replete with vitamin D versus those with vitamin D deficiency or insufficiency (odds ratio, 1.33). In five studies with 1,700 women, the likelihood of achieving a positive pregnancy test was higher for women replete in vitamin D versus those who were deficient or insufficient in vitamin D (odds ratio, 1.34). Based on data from all 11 studies, the likelihood of clinical pregnancy was higher in women replete with vitamin D (odds ratio, 1.46). There was no correlation for miscarriage with vitamin D concentration based on data from six studies that included 1,635 patients.

"The findings of this systematic review show that there is an association between vitamin D status and reproductive treatment outcomes achieved in women undergoing ART," the authors write. "Our results show that vitamin D deficiency and insufficiency could be important conditions to treat in women considering ARTs."

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »